Trial Profile
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Gallium 68 satoreotide (Primary) ; Lutetium 177 satoreotide tetraxetan (Primary)
- Indications Carcinoid tumour; Colorectal cancer; Gastric cancer; Lung cancer; Neuroendocrine tumours; Pancreatic cancer; Rectal cancer; Renal cancer
- Focus First in man; Therapeutic Use
- 10 Dec 2020 Status changed from active, no longer recruiting to completed.
- 27 Apr 2020 Planned End Date changed from 1 Nov 2020 to 1 Nov 2021.
- 27 Apr 2020 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2021.